Credit Acceptance's settlement reveals how predatory auto lending actually works at scale

Credit Acceptance agreed to pay $710 million to settle charges from 40 states that it knowingly steered low-income borrowers into loans designed to fail, trapping them in debt they could never realistically repay.

This is not a story about a few bad actors at a branch level: regulators from nearly every state concluded this was the business model, which makes the settlement one of the most significant consumer-finance accountability moments in years.

Ultragenyx's FDA approval proves rare-disease gene therapy is becoming a real commercial category

The FDA approved Ultragenyx's gene therapy for a rare and previously fatal disease, validating years of pipeline investment in a field that has historically struggled to get treatments across the finish line.

For a small biotech whose entire identity is built around diseases most drug companies ignore, a green light like this is not just a product launch but proof the strategy works, and the market rewarded it accordingly.

Lockheed Martin's single day of wins shows how defense contractors benefit from a world on edge

In one day, Lockheed Martin secured a $24.3 billion fighter jet sale to Saudi Arabia, received the first parts from its new manufacturing partnership with General Motors, and unveiled a next-generation missile alongside a new Pentagon production agreement, a sweep that would be remarkable in any month, let alone a single Thursday.

The General Motors partnership is the detail worth watching: it exists specifically because the Pentagon is worried it cannot produce enough munitions fast enough to meet simultaneous demands from Ukraine and the Middle East, and Lockheed is now the company threading that needle.